1. Search Result
Search Result
Results for "

HCV

" in MedChemExpress (MCE) Product Catalog:

245

Inhibitors & Agonists

3

Screening Libraries

4

Fluorescent Dye

1

Biochemical Assay Reagents

21

Peptides

1

Inhibitory Antibodies

22

Natural
Products

5

Recombinant Proteins

13

Isotope-Labeled Compounds

9

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-138305

    HCV Infection Inflammation/Immunology
    HCV-IN-31 (compound 4) is a HCV inhibitor, with an EC50/EC95 of 15.7 μM for HCV replicon .
    <em>HCV</em>-IN-31
  • HY-144108

    HCV Infection
    HCV-IN-35 (Compound (R)-3h) is a potent inhibitor of HCV. HCV-IN-35 has the potential for the research infection diseases .
    <em>HCV</em>-IN-35
  • HY-155832

    HCV Infection
    HCV-IN-44 (compound 28) is an HCV NS5B protein inhibitor that can effectively inhibit the replication of HCV virus. HCV-IN-44 can be used for the study of HCV infection .
    <em>HCV</em>-IN-44
  • HY-155831

    HCV Infection
    HCV-IN-43 (compound 2) is an HCV NS5B protein inhibitor that can effectively inhibit the replication of HCV virus. HCV-IN-43 can be used for the study of HCV infection .
    <em>HCV</em>-IN-43
  • HY-144110

    HCV Infection
    HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV-IN-37 is primarily driven by the inhibitory effect on the virus entry stage .
    <em>HCV</em>-IN-37
  • HY-133018

    HCV Infection
    HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC50s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity .
    <em>HCV</em>-IN-7
  • HY-133018A

    HCV Cancer
    HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC50s of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 hydrochloride has anti-viral activity .
    <em>HCV</em>-IN-7 hydrochloride
  • HY-147763

    HCV Infection
    HCV-IN-39 (Compound 18a) is a potent hepatitis C virus (HCV) nucleoside inhibitor with EC50 values of 0.644, 0.952 and 0.154 μM against GT1a, GT1b and GT1b CES1 replicons .
    <em>HCV</em>-IN-39
  • HY-147764

    HCV Infection
    HCV-IN-40 (Compound 18c) is a potent, orally active hepatitis C virus (HCV) nucleoside inhibitor with EC50 values of 0.259, 0.434 and 0.069 μM against GT1a, GT1b and GT1b CES1 replicons .
    <em>HCV</em>-IN-40
  • HY-P4035

    HCV Infection
    HCV NS4A Protein (18-40) (JT strain) is an HCV NS4A peptide, which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease .
    <em>HCV</em> NS4A Protein (18-40) (JT strain)
  • HY-115989

    HCV Infection
    HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC50=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile .
    <em>HCV</em>-IN-38
  • HY-147885

    HCV Infection
    HCV-IN-41 (compound 4) is a highly potent hepatitis C virus (HCV) inhibitor with an EC50 value of 0.006762 nM, 5.183 nM, 1.365 nM and 142.2 nM for HCV genotype 1b, 2a, 3a and 4a, respectively. HCV-IN-41 reduces HCV RNA replication .
    <em>HCV</em>-IN-41
  • HY-P4033

    HCV Infection Inflammation/Immunology
    HCV Peptide (257-266) is a peptide. HCV Peptide (257-266) can be used for the research of hepatitis C virus (HCV) .
    <em>HCV</em> Peptide (257-266)
  • HY-P4031

    HCV Infection Inflammation/Immunology
    HCV Peptide (131-140) is a peptide. HCV Peptide (131-140) can be used for the research of hepatitis C virus (HCV) .
    <em>HCV</em> Peptide (131-140)
  • HY-144106

    HCV Infection
    HCV-IN-33 (Compound (S)-3i) is an HCV entry inhibitor .
    <em>HCV</em>-IN-33
  • HY-144107

    HCV Infection
    HCV-IN-34 (compound 3i) is an orally active and potent HCV entry inhibitor. HCV-IN-35 shows excellent antiviral activity, with an EC50 of 0.010 μM and a CC50 (half-maximal cytotoxic concentration) of 8.23 μM .
    <em>HCV</em>-IN-34
  • HY-18564

    HCV Infection
    HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor, with an IC50 of 20 μM, a Kd of 29 μM.
    <em>HCV</em>-IN-3
  • HY-136266

    HCV Cancer
    HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e .
    <em>HCV</em>-IN-29
  • HY-144109

    HCV Infection
    HCV-IN-36 (compound (S)-3h) is an orally active and potent HCV entry inhibitor. HCV-IN-36 shows excellent antiviral activity, with an EC50 of 0.016 μM and a CC50 (half-maximal cytotoxic concentration) of 8.78 μM .
    <em>HCV</em>-IN-36
  • HY-136267

    HCV Infection
    HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC50s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .
    <em>HCV</em>-IN-30
  • HY-P4037

    HCV Infection
    HCV Core Protein (107-114) is a least immunogenic residue of the major linear HCV core regions. HCV Core Protein (107-114) is identified as the binding site within the region 101-118, which contains two residues differing between genotypes Ⅰ/Ⅱ and Ⅲ/Ⅵ. HCV Core Protein (107-114) might be a potential site for dissemination of HCV serotypes .
    <em>HCV</em> Core Protein (107-114)
  • HY-P4036

    HCV Infection
    HCV Core Protein (59-68) is a peptide containing residues 59-68 of the HCV core protein .
    <em>HCV</em> Core Protein (59-68)
  • HY-P4029

    HCV Infection
    HCV-1 e2 Protein (484-499) is a peptide consisting of 16 amino acids. HCV-1 e2 Protein (484-499) is derived from the envelope 2 protein of hepatitis C virus in the sera from individuals with antibodies to HCV .
    <em>HCV</em>-1 e2 Protein (484-499)
  • HY-P4027

    HCV Infection
    HCV-1 e2 Protein (554-569) is one of the main antigenic regions of HCV envelope 2 (e2) protein. The HCV-1 e2 Protein (554-569) contains a putative n-glycosylation site, which was previously thought to influence the immune recognition of e2 .
    <em>HCV</em>-1 e2 Protein (554-569)
  • HY-P4032

    HCV Inflammation/Immunology
    HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .
    <em>HCV</em> Peptide (35-44)
  • HY-P4027A

    HCV Infection
    HCV-1 e2 Protein (554-569) TFA is one of the main antigenic regions of HCV envelope 2 (e2) protein. The HCV-1 e2 Protein (554-569) TFA contains a putative N-glycosylation site, which was previously thought to influence the immune recognition of e2 .
    <em>HCV</em>-1 e2 Protein (554-569) (TFA)
  • HY-14775
    Nesbuvir
    5+ Cited Publications

    HCV-796

    HCV Infection
    Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.
    Nesbuvir
  • HY-P0162

    HCV Infection
    HCV-IN-4 is a potent and orally active HCV NS5A inhibitor, shows great potency against GT1a, GT2b, GT3a, GT1a Y93H and GT1a L31V, with EC90s of 3 pM, 0.3 nM, 0.01 nM, 0.5 nM and 0.02 nM, respectively .
    <em>HCV</em>-IN-4
  • HY-50680

    HCV Protease Infection
    HCVP-IN-1 (compound 1) is a hepatitis C viral polymerase (HCVP) inhibitor .
    HCVP-IN-1
  • HY-112047

    GSK2878175

    HCV Infection
    GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .
    GSK8175
  • HY-19558

    HCV HCV Protease Infection
    IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM) .
    IDX184
  • HY-111087

    HCV Protease Infection Inflammation/Immunology
    AZD-7295 is a HCV NS5A protein inhibitor, with an EC50 of 7 nM for GT-1b replicon .
    AZD-7295
  • HY-109047

    AL-335

    HCV DNA/RNA Synthesis Infection
    Adafosbuvir (AL-335), a precursor compound of a uridine-based nucleotide analog polymerase (NS5B) inhibitor, has potent antiviral activity against HCV and acts as a potent inhibitor of HCV RNA polymerase .
    Adafosbuvir
  • HY-133248

    Drug Metabolite Others
    Daclatasvir Impurity C is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .
    Daclatasvir Impurity C
  • HY-133247

    Drug Metabolite Others
    Daclatasvir Impurity B is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .
    Daclatasvir Impurity B
  • HY-156051

    HCV Infection
    Tetrazolast is a HCV inhibitor with the inhibitory activity ranging from 5% to 20%, extracted from patent WO2005030774.
    Tetrazolast
  • HY-13998
    Dasabuvir
    10+ Cited Publications

    ABT-333

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir
  • HY-13998A

    ABT-333 sodium

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir sodium
  • HY-I0179

    HCV Protease Infection
    ITMN 4077 is a macrocyclic inhibitor against Hepatitis C Virus (HCV) NS3 protease (EC50: 2131 nM) .
    ITMN 4077
  • HY-133246

    Daclatasvir Impurity A

    HCV Infection
    Monodes(N-carboxymethyl)valine Daclatasvir (Daclatasvir Impurity A) is the main degradation product of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .
    Monodes(N-carboxymethyl)valine Daclatasvir
  • HY-15591

    HCV Infection
    TMC647055 is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication. TMC647055 has potent HCV combine activity with an IC50 value of 82 nM. TMC647055 can be used for the research of Hepatitis C virus (HCV) .
    TMC647055
  • HY-P2502

    HCV Protease HCV Infection
    Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a Ki of 41 nM .
    Hepatitis Virus C NS3 Protease Inhibitor 2
  • HY-148647

    ISIS 301012 free base

    HCV Infection
    Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .
    Mipomersen
  • HY-15591A
    TMC647055 Choline salt
    1 Publications Verification

    HCV Infection
    TMC647055 (Choline salt) is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication. TMC647055 Choline salt has potent HCV combine activity with an IC50 value of 82 nM. TMC647055 Choline salt can be used for the research of Hepatitis C virus (HCV) .
    TMC647055 Choline salt
  • HY-126973

    HCV Protease Infection
    BI-1230 is potent and digit nanomolar inhibitor of HCV NS3 protease and of viral replication. BI-1230 is also highly selective against other serine/cysteine proteases. BI-1230 shows good Pharmacokinetic(PK) activity .
    BI-1230
  • HY-101634

    HCV Infection
    ABT-072 is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC50=1 nM; HCV GT1b EC50=0.3 nM) .
    ABT-072
  • HY-147358A

    Emitasvir; DAG-181

    HCV Infection
    Yimitasvir (Emitasvir) is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor. Yimitasvir can be used for research of chronic HCV infection .
    Yimitasvir
  • HY-101634A

    HCV Infection
    ABT-072 (potassium trihydrate) is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC50=1 nM; HCV GT1b EC50=0.3 nM) .
    ABT-072 potassium trihydrate
  • HY-16593

    HCV Protease Infection
    GS-9256 is a selective HCV NS3 protease inhibitor. GS-9256 has good pharmacokinetic properties and antiviral activity .
    GS-9256
  • HY-109035
    Inarigivir soproxil
    1 Publications Verification

    SB9200; GS-9992

    HCV HBV Infection
    Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .
    Inarigivir soproxil

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: